A detailed history of Geode Capital Management, LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 551,039 shares of AMLX stock, worth $2.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
551,039
Previous 468,866 17.53%
Holding current value
$2.91 Million
Previous $890,000 100.56%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.65 - $3.24 $135,585 - $266,240
82,173 Added 17.53%
551,039 $1.79 Million
Q2 2024

Aug 09, 2024

SELL
$1.62 - $2.71 $967,753 - $1.62 Million
-597,379 Reduced 56.03%
468,866 $890,000
Q1 2024

May 13, 2024

BUY
$2.71 - $19.57 $96,283 - $695,302
35,529 Added 3.45%
1,066,245 $3.03 Million
Q4 2023

Feb 13, 2024

BUY
$12.07 - $18.46 $587,181 - $898,042
48,648 Added 4.95%
1,030,716 $15.2 Million
Q3 2023

Nov 13, 2023

BUY
$18.08 - $23.45 $796,803 - $1.03 Million
44,071 Added 4.7%
982,068 $18 Million
Q2 2023

Aug 11, 2023

BUY
$20.98 - $31.42 $986,374 - $1.48 Million
47,015 Added 5.28%
937,997 $20.2 Million
Q1 2023

May 15, 2023

BUY
$27.71 - $40.93 $1.03 Million - $1.52 Million
37,069 Added 4.34%
890,982 $26.1 Million
Q4 2022

Feb 13, 2023

BUY
$29.75 - $39.26 $6.5 Million - $8.57 Million
218,357 Added 34.36%
853,913 $31.6 Million
Q3 2022

Nov 14, 2022

BUY
$17.15 - $30.92 $6.93 Million - $12.5 Million
404,139 Added 174.64%
635,556 $17.9 Million
Q2 2022

Aug 12, 2022

BUY
$6.85 - $19.93 $282,678 - $822,451
41,267 Added 21.7%
231,417 $4.46 Million
Q1 2022

May 13, 2022

BUY
$12.85 - $32.9 $2.44 Million - $6.26 Million
190,150 New
190,150 $2.44 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $310M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.